CTOs on the Move

A2 Biotherapeutics

www.a2bio.com

 
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

A2 Biotherapeutics raised $57M on 11/05/2019
A2 Biotherapeutics raised $71.5M on 10/06/2020

Similar Companies

NationalAccessCannabis

We are dedicated to health and to working in consultation with health professionals. We are committed to responsibility, through our secure non-transferable medical cannabis access card system. A system we are establishing in consultation with law enforcement to achieve national recognition.

ALCON LABORATORIES INC

ALCON LABORATORIES INC is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

3-V Biosciences

3-V Biosciences, Inc. is discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company`s lead candidate is a first-in-class, oral fatty acid synthase (FASN) inhibitor in Phase 1 clinical development that has been shown to block tumor cell signaling pathways and induce tumor cell apoptosis. 3-V`s antiviral therapeutics have demonstrated the ability to block host-pathogen interactions, resulting in robust and broad-spectrum in vitro and in vivo antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.

Metavention

Metavention is a venture-backed medical device company founded in 2012 that is developing a novel glucose control therapy for patients with type 2 diabetes. Metabolic Neuromodulation Therapy (MNT) is a simple cardiovascular procedure intended to modulate sympathetic nervous system activity in patients with Type 2 diabetes for the purpose of lowering blood glucose levels. MNT was developed based on published scientific data and extensive animal studies suggesting a link between elevated sympathetic nerve activity in the metabolic system and increased levels of blood glucose. MNT is currently being studied in human clinical trials and represents a potentially important new treatment option for patients with Type 2 Diabetes.

PowerMedica

PowerMedica is a Deerfield Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.